BioSpace News Archive

Galmed Pharmaceuticals Ltd. announced today that the United States Patent and Trademark Office (USPTO) granted Galmed new patents related to the use of Aramchol for the treatment of fibrosis and for the treatment for modulating gut microbiota.

Cybin Inc. today announced that an Institutional Review Board (“IRB”) has approved a Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow.

ACELYRIN, INC. today announced the appointment of Melanie Gloria, BSN, as the company’s chief operating officer (COO).

Applied Genetic Technologies Corporation today announced it had exceeded the enrollment target in the Company’s SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP).

Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today provided an update on recent corporate developments.

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, announced it has appointed Dana Brown and Timothy Norris Irish as new independent members of the Board of Directors, effective January 10, 2022.

SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration has approved the Investigational New Drug Application, for our first development candidate, enabling the company to initiate the first clinical trial in humans with SNIPR001.

AlzeCure Pharma AB announced that an abstract on its research platform NeuroRestore in mitochondrial function has been accepted for an oral presentation at AD/PD 2022, which this year will be held in Barcelona on March 15-20.

Progenity, Inc. today announced that patient data on indicators of efficacy in the treatment of gastrointestinal disorders has been accepted for oral presentation during the 34th edition of the Belgian Week of Gastroenterology, February 9-11, 2022.

Sana Biotechnology, Inc. announced that the company entered into an agreement with the National Cancer Institution, an institute of the National Institutes of Health, for worldwide exclusive commercial rights to the NIH’s CD22 chimeric antigen receptor with a fully-human binder for use in certain in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.